By InvitationNot Applicable

Lactose Intolerance and Intestinal Permability

Turkey (Türkiye)200 participantsStarted 2026-02-10

Plain-language summary

"This study evaluates the interplay between lactose intolerance, intestinal barrier function (zonulin), and intestinal inflammation (fecal calprotectin) in adults, aiming to clarify their independent contributions to symptom severity and quality of life."

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults aged 18-70 years; experiencing chronic symptoms (diarrhea, bloating, abdominal pain, constipation, flatulence) for the past 3 months, potentially fitting IBS criteria. Exclusion Criteria: \- Acute gastroenteritis (\< 4 weeks), Active gastrointestinal bleeding (stomach, small intestine, and colon), Known celiac disease, Bariatric surgery or short bowel syndrome, Pregnancy or lactation, Type I and II Diabetes mellitus, Antibiotic use within the last 2 weeks, High-dose NSAIDs within the last 2 weeks, Initiation of probiotics or prebiotics within the last 4 weeks, High-dose PPI use (optional), Inflammatory bowel disease (IBD; ulceretive colitis and Crohn's colitis) with active severe flare (excluded from primary analyses, evaluated separately in subgroup analyses)

What they're measuring

To determine the relationship between lactose intolerance (LI) and fecal biomarkers, zonulin (Z) and fecal calprotectin (FC), in adults with IBS.

Timeframe: Baseline assessment (single time point measurement of biomarkers and symptoms)

Trial details

NCT IDNCT07424898

SponsorBezmialem Vakif University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-12-15

View on ClinicalTrials.gov More Lactose Intolerance, Adult Type trials